Amicus Therapeutics (FOLD) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Amicus Therapeutics Announces Second Quarter 2016 Financial Results and Corporate Updates
August 9, 2016 7:31 AM EDT
Significant Progress with EU Galafold Launch and Regulatory Submissions
Enrollment in Pompe Phase 1/2 Clinical Study on Track with Initial Data Expected in 2H16
Elevation of Time to Wound Closure as Co-Primary Endpoint in Ongoing Phase 3 Study of SD-101 for Epidermolysis Bullosa
$130 Million in Equity and Debt Proceeds Since March 31
CRANBURY, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) --... More
